Company

Cambrian Biopharma

Last updated 2026-05-30· 1 min read

Reviewed by the Ultimate Longevity Bible editorial team. Educational reference — not medical advice. See disclaimer.

What it is

Cambrian Biopharma (founded 2019) operates a portfolio of biotech subsidiaries each targeting a specific hallmark of aging. The model is similar to Juvenescence and Life Biosciences but with tighter operational integration — subsidiaries share R&D, clinical, and regulatory infrastructure.

Subsidiary programmes (publicly disclosed)

Solanum Biosciences: senescence-focused.
Verdure Bio: cellular reprogramming.
Nirogy Therapeutics: monoamine-transporter modulation for metabolic disease.
Tornado Therapeutics: ferroptosis programmes.
Several others.

Lead clinical assets

A first-in-human readout of one Cambrian-subsidiary asset is expected to provide the first proof-of-concept for the portfolio.

Funding

Series B round in 2022 brought total funding to ~$160M.

Business model context

Cambrian's operating-company thesis is that longevity biotech is best tackled portfolio-style: many parallel bets, each targeting one mechanism, sharing capital-intensive functions (regulatory, clinical operations, translational science). Similar in shape to Juvenescence and Life Biosciences, the model bets on diversification against per-asset failure risk in a field where any single mechanism-of-action carries substantial uncertainty.

Track-record markers to watch

First-in-human readout of any Cambrian subsidiary drug — a proof of the operating-company thesis.
Follow-on capital: whether Series C is achievable in the current biotech financing environment.
Any pivot away from the multi-subsidiary structure would signal operational stress on the shared-services model.

Cambrian sits in an unusual position: not a single-asset biotech (where investors know exactly what they're buying) and not a fund (where diversification is the product). Its success depends on the operational thesis being right AND at least one subsidiary asset translating.